A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new drug also offers the ability to have its effects reversed quickly.
If you enjoy this content, please share it with a colleague
- Read more about New Antiplatelet Drug May Offer Benefits Over Clopidogrel
- Log in or register to post comments